Industry

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 34% Compared to Tislelizumab Plus Chemotherapy; Hazard Ratio 0.66 First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC Tolerable Safety Profile Consistent with Prior Clinical Trial … [Read more…]

ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD) by 24 weeks, with a median maximal cognitive decline of -15.8% for NUBEQA versus -36.1% with enzalutamide (p=0.009) in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) or metastatic … [Read more…]

Salubris Biotherapeutics Announces Updated Phase 1/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the 2026 American Society of Clinical Oncology Annual Meeting

Robust enrollment of 173 patients across dose escalation and expansion cohorts, with objective responses observed across five tumor types JK06 continued to demonstrate a highly differentiated MMAE safety profile with predominantly low-grade, manageable treatment-related adverse events (TRAEs) at doses selected for expansion cohorts Objective response rate (ORR) of 50% (5 of 10) among response-evaluable squamous … [Read more…]

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

– Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) – Late-breaking Phase 2b AZURE-1 results demonstrate efficacy and safety of brelovitug for the treatment of chronic hepatitis delta virus (HDV), including in patients with advanced disease – Treatment with LIVMARLI® (maralixibat) demonstrates improved event-free … [Read more…]

Massive Bio Announces Next-Generation Reticulum Nexus™ Product Suite at ASCO 2026

Sentinel Agents™, NexusPulse™ Intelligent Calculators, DrArturo AI™, Phoebe AI™, Patient Connect™, and TrialRelay™ create a real-time multi-agent orchestration layer for precision oncology access CHICAGO–(BUSINESS WIRE)–Massive Bio today announced the next-generation product suite within Reticulum Nexus™, introducing a coordinated set of AI agents, intelligent calculators, signal engines, patient navigation tools, and physician referral workflows designed to … [Read more…]

Tanner Introduces New AI Voice Chat Assistant to Reduce Call Center Hold Times

The new voice chat AI assistant, Clara, provides 24/7 bilingual support to streamline inbound calls, handle common questions and reduce on-hold times. CARROLLTON, Ga.–(BUSINESS WIRE)–Tanner Health, a leading nonprofit healthcare system serving west Georgia and east Alabama, today announced its go-live with Hyro, the leading Responsible AI Assistant Platform for health care, to streamline patient … [Read more…]

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node involvement Study shows for the first time, based on the Prosigna test results, that more than two-thirds of patients could be spared chemotherapy without compromising outcomes SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$VCYT #ASCO26–Veracyte, … [Read more…]

Foundation Medicine Launches FoundationOne®MRD, First-of-Its-Kind Molecular Residual Disease Test to Combine Structural Variants and Digital PCR

Enables ultra-sensitive molecular disease detection, with high specificity Provides accelerated results, with the personalized tumor fingerprint and initial blood test expected within approximately 2 to 3 weeks from the sample receipt, and subsequent blood test results anticipated within 1 to 3 days BOSTON–(BUSINESS WIRE)–Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced the … [Read more…]

Concert for Cures Series Surpasses $28 Million Raised for Cancer Research Following P!NK’s Electrifying Performance at Petco Park

Curebound’s annual benefit concert with headliner P!NK raises over $8.25 million in one night for cancer research, joining a roster of past headliners that includes Elton John, Ed Sheeran and Alicia Keys. SAN DIEGO–(BUSINESS WIRE)–#CancerResearch—Curebound, a cancer research accelerator, today announced that its 2026 Concert for Cures, headlined by global music icon P!NK, raised $8.25 … [Read more…]

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund

TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of … [Read more…]